Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Documenti analoghi

• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  di: Nishino, Mizuki, et al.
  Pubblicazione: (2016)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  di: Lo, Peter C., et al.
  Pubblicazione: (2015)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  di: Chaft, Jamie E., et al.
  Pubblicazione: (2011)
• Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
  di: Mak, Raymond H., et al.
  Pubblicazione: (2011)
• New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2011)